NCT05546268
Study of Oral MRT-2359 in Selected Cancer Patients treatment 1 / 2 recruiting NCT05579366
PRO1184 for Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT06639672
Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer No drug interventions treatment 2 not_yet_recruiting NCT06404463
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer treatment 2 not_yet_recruiting NCT06343948
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer treatment 3 recruiting NCT03394027
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma treatment 2 completed NCT04443348
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) treatment 2 recruiting NCT03560856
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer treatment 2 unknown_status NCT05455619
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer treatment 1 / 2 recruiting NCT05809024
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy treatment 4 recruiting NCT05159518
A Study of PRT2527 in Participants With Advanced Solid Tumors No drug interventions treatment 1 completed NCT04802876
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors treatment 2 recruiting NCT02791334
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors treatment 1 active_not_recruiting NCT05234606
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors treatment 1 / 2 withdrawn NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors treatment 1 recruiting NCT06201234
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer No drug interventions treatment 2 recruiting NCT06257264
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors treatment 1 recruiting NCT06369285
A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer treatment 2 recruiting NCT05878314
Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer No drug interventions Not Available Not Available recruiting NCT02692755
Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer treatment 2 / 3 completed NCT05901428
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer treatment 3 recruiting NCT05608252
VS-6766+Abema+Fulv in Met HR+/HER- BC treatment 1 / 2 recruiting NCT05573126
Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer No drug interventions treatment 1 / 2 recruiting NCT03613220
CompLEEment-1 Canadian Correlative Sub-Study other 2 completed NCT06611813
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) treatment 2 recruiting NCT06599216
Adebrelimab Combined with Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer treatment 2 not_yet_recruiting NCT06470633
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer treatment 2 not_yet_recruiting NCT02983045
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors treatment 1 / 2 completed NCT05633914
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer treatment 2 recruiting NCT06447623
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer treatment 3 recruiting NCT05789771
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. Not Available Not Available completed NCT04282031
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer treatment 1 / 2 recruiting NCT05889871
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer treatment 3 not_yet_recruiting